Saturday, November 25, 2023
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

FDA OKs Symplicity Renal Denervation System for Hypertension

November 20, 2023
in Health News
Share on FacebookShare on Twitter


The US Food and Drug Administration (FDA) has approved Medtronic’s Symplicity Spyral renal denervation system for the treatment of hypertension, the company has announced.

The Symplicity Spyral system, also known as the Symplicity blood pressure procedure, provides a catheter-based approach to denervate the renal arteries using radiofrequency energy.

Back in August, the FDA’s Circulatory System Devices Panel unanimously agreed that the Symplicity Spyral system is safe, but the panel was split on its efficacy and whether the benefits outweighed the risks associated with its use, as reported by Medscape Medical News.

As part of the Medtronic SPYRAL HTN Global Clinical Program, more than 25,000 patients have been treated worldwide, both in the presence and absence of medication, and in patients with high baseline cardiovascular risk.

The SPYRAL HTN-OFF study enrolled patients with hypertension whose medications could be stopped at the start of the trial.

The primary effectiveness endpoint was the mean difference in the baseline adjusted 24-hour ambulatory systolic blood pressure (ASBP) from baseline to 3 months after renal denervation or sham procedure. The study showed a statistically significant reduction of 3.9 mm Hg ASBP in patients who received the device compared with sham-control patients.

The SPYRAL HTN-ON study evaluated patients with uncontrolled hypertension who continued taking their blood pressure medications during treatment with either the Spyral renal denervation device or a sham device.

The primary endpoint was the mean difference in the baseline adjusted 24-hour ambulatory systolic blood pressure at 6 months. The study showed a nonsignificant 24-hour 0.03 mm Hg reduction in ambulatory systolic blood pressure in active-treatment patients compared with sham-control patients.

“The Symplicity blood pressure procedure is safe and effective, providing significant ‘always on’ blood pressure reductions for patients,” David Kandzari, MD, chief, Piedmont Heart Institute, and co-principal investigator of the SPYRAL clinical program, said in the news release.

“This approval paves the way for a transformation in hypertension treatment, offering a solution that complements medication and lifestyle changes,” added co-principal investigator Raymond Townsend, MD, with University of Pennsylvania School of Medicine.

Medtronic notes that patient preference and shared decision-making are key components when considering the Symplicity blood pressure procedure.

In a patient preference study led by Medtronic, when presented with an interventional treatment with blood pressure reduction and potential risks in line with those of the Symplicity blood pressure procedure, approximately one third of patients were likely to choose the interventional treatment.

Earlier this month, the FDA also approved the Paradise Ultrasound Renal Denervation system (Recor Medical Inc, Otsuka Medical Devices Co Ltd) for the treatment of hypertension, as reported by Medscape Medical News.



Source link : https://www.medscape.com/viewarticle/998664?src=rss

Author :

Publish date : 2023-11-20 19:14:05

Copyright for syndicated content belongs to the linked Source.
Previous Post

Bayer Recalls One Lot of Cancer Drug Vitrakvi

Next Post

Asundexian Phase 3 AF Study Halted for Lack of Efficacy

Related Posts

Health News

Future of Atopic Dermatitis Management

November 25, 2023
Health News

Early Interventions for Autism; Imaging After Stenting

November 25, 2023
Health News

We Need ICD Codes for Climate-Linked Health Outcomes

November 25, 2023
Health News

John Lewis to offer health checks to customers

November 24, 2023
Health News

4 Tips To Stay Safe on Your Vacation

November 24, 2023
Health News

Clinical Challenges: Diagnosing Axial Spondyloarthritis

November 24, 2023
Load More

Future of Atopic Dermatitis Management

November 25, 2023

Early Interventions for Autism; Imaging After Stenting

November 25, 2023

We Need ICD Codes for Climate-Linked Health Outcomes

November 25, 2023

John Lewis to offer health checks to customers

November 24, 2023

4 Tips To Stay Safe on Your Vacation

November 24, 2023

Clinical Challenges: Diagnosing Axial Spondyloarthritis

November 24, 2023

I Love Being the ‘ER Dad’

November 24, 2023

Epinephrine Was First an Asthma Treatment

November 24, 2023
Load More

Categories

Archives

November 2023
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Oct    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

FDA OKs Symplicity Renal Denervation System for Hypertension- & https://www.lingedelitpascher.com/   https://vinsdivins.fr   https://www.cap-neree-services.com   https://www.boutiqueanimalerie.com/   https://chaussuresx.fr   https://artfine.net   https://websites4sell.com   https://ventilateurdeplafond.org   -/- After perfect October, can Blue Hens have a November to remember with questions at QB?   One stat to know for all 32 NFL teams in Week 9 + TNF preview   Rocket EAGC44BK Guitare électro-acoustique à pan coupé Noir   Paris 'bouquinistes' resist plans to remove riverside book kiosks for 2024 Olympics   ‘We will heal together’: Maine residents relieved as suspected gunman found dead   -*- Get this Black Friday deal for 30% off my pick for best iPhone case and Apple Watch band   Meta Quest 2 for $200 might be the best Black Friday deal still available   Simone Inzaghi insists he expected Juventus to be this competitive   Future of Atopic Dermatitis Management   Bayrol Quicktest Ph-Plus 2294550, 1.0 kg   Tommy Hilfiger Eton Leather Mini Credit Card Men’s Wallet, Black One Size   ROTHENBERGER Heiz – Strahler inkl. Piezo Zündung, Schlauch & Regler, Gasheizstrahler, Aufsatzheizstrahler, betrieben mit…   Merrell Capra Mid GTX 5, Chaussures de Randonnée Hautes Femme   $ FDA OKs Symplicity Renal Denervation System for Hypertension * FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | FDA OKs Symplicity Renal Denervation System for Hypertension | | FDA OKs Symplicity Renal Denervation System for Hypertension | | FDA OKs Symplicity Renal Denervation System for Hypertension | | FDA OKs Symplicity Renal Denervation System for Hypertension |

NEWSHEALTH : FDA OKs Symplicity Renal Denervation System for Hypertension